



FINANCIAL TEAR SHEET

CORPORATE PROFILE

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin's Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.

PRIMARY IR CONTACT

Marianne M. Lambertson
Vice President, Corporate
Communications

Phone: 781-292-4273

E-mail:

mlambertson@verastem.com

STOCK PERFORMANCE

VSTM (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$3.20
Change (%)	▼ 0.07 (2.14%)
Volume	453,956
52 Week Low	\$1.11
Market Cap	\$154,777,296
Rolling EPS	-1.65
PE Ratio	N/A
Shares Outstanding	48,367,905

Data as of 02/23/18 4:00 p.m. ET



RECENT HEADLINES & EVENTS

02/07/18 - 7:00 a.m.

[Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma](#)

02/06/18 - 4:06 p.m.

[Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635\(c\)\(4\)](#)

01/26/18 - 2:45 p.m.

[Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model](#)

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
02/14/18	SC 13G/A
02/06/18	5
01/26/18	SC 13G
01/09/18	4

CORPORATE GOVERNANCE

[Robert Forrester, LL.B.](#) President/Chief Executive Officer

[Dan Paterson](#) Chief Operating Officer

[Steven Bloom](#) Chief Strategy Officer

[Julie Feder](#) Chief Financial Officer

[Diep Le, M.D, Ph.D.](#) Chief Medical Officer

[Joseph Lobacki](#) Chief Commercial Officer

[Jonathan Pachter, Ph.D.](#) Chief Scientific Officer

[Hagop Youssoufian, MSc, M.D.](#) Head of Hematology and Oncology Development

Powered by **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed